<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975698</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN1903</org_study_id>
    <secondary_id>2U10HL069294-11</secondary_id>
    <nct_id>NCT04975698</nct_id>
  </id_info>
  <brief_title>HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903</brief_title>
  <acronym>BMTCTN1903</acronym>
  <official_title>Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue - Auto -RESIST. BMTCTN1903</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catherine Bollard</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT)&#xD;
      followed by administration of HST-NEETs for treatment of HIV associated lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants will have 100-120 mL of peripheral blood collected and shipped to&#xD;
      Children's National Hospital at ambient temperature. The peripheral blood will be used to&#xD;
      manufacture the HST-NEET product. The autologous peripheral blood stem cell graft suitable&#xD;
      for rescue following conditioning will be obtained either before or after the collection of&#xD;
      blood to generate HST-NEETs. Pre-transplant conditioning will consist of BEAM; BCNU 300 mg/m2&#xD;
      on Day -6, Etoposide 100 mg/m2 BID and Ara-C 100 mg/m2 BID on Days -5, -4, -3 and -2 and&#xD;
      Melphalan 140 mg/m2 on Day -1. ASCT on Day 0. If the mobilized graft contains greater than&#xD;
      5.0 x 106 CD34+ cells per kg, any additional cells should be cryopreserved as a &quot;back-up&quot;&#xD;
      graft in the event of graft failure related to the HST-NEETs. Participants will receive one&#xD;
      dose (2 x 107 cells/m2 ) of HST-NEETs between Days +3 to +7 based on the clinical condition&#xD;
      of the participant (as outlined in Section 2.6). If this window is missed, the HST-NEETs may&#xD;
      be administered up to Day +30 post-ASCT. Participants will be followed for at least one year&#xD;
      after ASCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants who can be treated with (HST-NEETs) within 1 week of ASCT in a cooperative multi-institutional setting and 2.) the efficacy of HSTNEETs in reducing the HIV intact proviral</measure>
    <time_frame>6 Months</time_frame>
    <description>Feasibility is defined as a participant receiving HST-NEETs within 1 week post-ASCT; Efficacy will be measured by the reduction in intact proviral reservoir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 Months and 1 Year</time_frame>
    <description>Participants are considered a failure for this endpoint if they die or if they relapse/progress or receive anti-lymphoma therapy, other than post-transplant consolidative localized radiation (maximum 3 sites) to sites of prior bulk disease pre-transplant (greater than 3cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of acute infusion related toxicities</measure>
    <time_frame>1 Year</time_frame>
    <description>Acute infusion related toxicities are defined as toxicities related to the infusion of HST-NEETs that occur within 24 hours of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of therapy on the HIV intact proviral reservoir</measure>
    <time_frame>1 Year</time_frame>
    <description>Impact on intact proviral reservoir will be assessed using the IPDA at 4-8 weeks prior to transplant and 12 months following ASCT</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to hematopoietic recovery</measure>
    <time_frame>1 Year</time_frame>
    <description>Time to neutrophil recovery will be the first of three consecutive labs of greater than or equal to 500 neutrophils/μL following the expected nadir. Time to platelet engraftment will be the date platelet count is greater than or equal to 20,000/μL for the first of three consecutive labs with no platelet transfusions 7 days prior.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>1 Year</time_frame>
    <description>The incidence of viral, fungal and bacterial infections will be tabulated. All Grade 2 and Grade 3 infections will be reported according to the BMT CTN Technical MOP from Day 0 up to 1 year post-transplant. Infections of interest will be captured and described. The incidence rate of infections is defined by the number of infections divided by the total person-time accumulated over the duration of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>6 Months 1 Year</time_frame>
    <description>Non-Relapse Mortality (NRM) is defined as death occurring in a participant without relapse progression and will be measured at 6 months and at 1 year.</description>
  </other_outcome>
  <other_outcome>
    <measure>Toxicities</measure>
    <time_frame>1 Year</time_frame>
    <description>Toxicities related to the BEAM conditioning regimen and HST-NEETs infusion beyond the 24 hour acute toxicity monitoring period will be defined by using the version 5.0 CTCAE criteria. All grades of toxicity related to HST-NEETs will be collected. Only grade 3 or higher conditioning regimen related toxicities will be collected.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of plasma DNA in blood (clonal Ig DNA) as a tumor marker</measure>
    <time_frame>6 Months 1 Year</time_frame>
    <description>Blood specimens will be collected prior to the initiation of conditioning, and at Days 100, 6 months and 1 year post-ASCT. The presence of clonal Ig DNA in plasma will be assessed at each of these time points.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of therapy on the HIV intact proviral reservoir</measure>
    <time_frame>100 Days</time_frame>
    <description>Impact on intact proviral reservoir assessed using the IPDA Day 100 post-ASCT as compared to baseline at 4-8 weeks prior to transplant.</description>
  </other_outcome>
  <other_outcome>
    <measure>HIV RNA in plasma</measure>
    <time_frame>100 Days, 6 Months, 1 Year</time_frame>
    <description>HIV RNA in plasma will be measured by a sensitive investigational single copy assay (SCA, detection limit 0.38 copy/ml). Blood specimens will be collected, and plasma HIV RNA measured, at study visits corresponding to those associated with IPDA testing: 4-8 weeks prior to transplant, and at Days 100, 6 months and 1 year post-ASCT.</description>
  </other_outcome>
  <other_outcome>
    <measure>HST-NEETs persistence and expansion in vivo</measure>
    <time_frame>100 Days, 6 Months, 1 Year</time_frame>
    <description>Persistence of HST-NEETs will be measured by frequency of HIV-1 antigen-specific (gag, pol, nef) CD8+ T-cells by ELIspot at baseline and post-infusion at timepoints at Days 100, 6 months, and 1 year post transplant. Change in T cell responses from baseline to post-infusion, measured by frequency of cells secreting IFN-γ by multimer analysis and/or intracellular cytokine staining and/or ELIspot and/or TCR sequencing will be done depending on PBMC cell numbers available and reagent availability.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>HIV Associated Lymphoma</condition>
  <arm_group>
    <arm_group_label>HST-NEETs</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive 2x107 /m2 cells as a single intravenous (IV) infusion. The cells will be cryopreserved ideally at 1x107 T cells per mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics.</description>
    <arm_group_label>HST-NEETs</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligible participants are HIV positive and plan to be treated by high dose chemotherapy&#xD;
        followed by an autologous stem cell transplant (ASCT). Participants are a minimum of 15&#xD;
        years of age with Karnofsky performance status greater than or equal to 70% that have&#xD;
        primary refractory or recurrent diffuse large B-cell, immunoblastic, plasmablastic, high&#xD;
        grade, Burkitt, primary effusion lymphoma, or classical Hodgkin lymphoma. Participants must&#xD;
        have received 2 or 3 prior treatment regimens, including an induction chemotherapy and 1 or&#xD;
        2 salvage regimens. Monoclonal antibody therapy and local radiation will not be counted as&#xD;
        prior therapies. Participants must have chemosensitive disease as demonstrated by complete&#xD;
        or partial response to induction or most recent salvage chemotherapy. Participants cannot&#xD;
        have had prior autologous, allogeneic HCT, or CART-cell therapy. Participants must initiate&#xD;
        conditioning therapy within 3 months of stem cell mobilization or bone marrow harvest.&#xD;
        Blood cell mobilization or bone marrow harvest will be carried out per institutional&#xD;
        guidelines. Participants may not have HIV refractory to pharmacologic therapy. Patients&#xD;
        must not have an uncontrolled infection. Participants must not have received previous&#xD;
        cellular therapy&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 15 years old or older at time of enrollment.&#xD;
&#xD;
          2. Receiving antiretroviral therapies (ART) with HIV viral load below the limit of&#xD;
             detection by standard commercial assay. A single plasma HIV-1 RNA measurement that is&#xD;
             ≥ the limit of quantification of the FDA-approved commercial assay but&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Karnofsky performance score less than 70%.&#xD;
&#xD;
          2. Participant is known to have an HIV subtype other than B.&#xD;
&#xD;
          3. Participant has documented raltegravir or protease inhibitor resistance.&#xD;
&#xD;
          4. Myocardial infarction within 6 months prior to enrollment or New York Heart&#xD;
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia.&#xD;
&#xD;
          5. Uncontrolled bacterial, viral or fungal infection (currently taking medication and&#xD;
             with progression or no clinical improvement).&#xD;
&#xD;
          6. Participant has active CNS involvement.&#xD;
&#xD;
          7. Participants with prior malignancies except resected non-melanoma skin cancer or&#xD;
             treated cervical carcinoma in situ. Cancer treated with curative intent greater than&#xD;
             or equal to 5 years previously will be allowed. Cancer treated with curative intent&#xD;
             less than 5 years BMT CLINICAL TRIALS NETWORK HIV T-Cell - Protocol 1903 Version 1.0&#xD;
             Dated February 24, 2021 2-4 Confidential previously may be eligible must be reviewed&#xD;
             and approved by the Protocol Officer or Chairs.&#xD;
&#xD;
          8. Female participants that are pregnant as per institutional definition or&#xD;
             breastfeeding.&#xD;
&#xD;
          9. Fertile men or women unwilling to use contraceptive techniques from the time of&#xD;
             initiation of mobilization until six-months post-transplant.&#xD;
&#xD;
         10. Prior autologous or allogeneic HCT, or prior therapy with chimeric antigen receptor&#xD;
             (CAR) T-cells.&#xD;
&#xD;
         11. Participants with evidence of MDS/AML or abnormal cytogenetic analysis indicative of&#xD;
             MDS on the pre-transplant bone marrow examination. Pathology report documentation need&#xD;
             not be submitted.&#xD;
&#xD;
         12. Steroids greater than 0.5 mg/kg/day prednisone equivalents.&#xD;
&#xD;
         13. Bone marrow involvement by lymphoma at time of workup. Prior history of bone marrow&#xD;
             involvement is allowed if cleared prior to ASCT.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Devine, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>National Marrow Donor Program</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Borchert</last_name>
    <phone>301-251-1161</phone>
    <phone_ext>12789</phone_ext>
    <email>bmtctn1903@emmes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Ritzau</last_name>
    <email>nritzau@emmes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Alvanas, MD</last_name>
      <email>jalvarnas@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kieron Dunleavy</last_name>
      <email>Kieron.M.Dunleavy@medstar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alex Lazaryan</last_name>
      <email>alexander.lazaryan@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jasper Barnes</last_name>
      <phone>404-851-6908</phone>
      <email>jasper.barnes@northside.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rich Ambinder</last_name>
      <email>rambind1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Monahan</last_name>
      <email>rmonahan@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Shelton</last_name>
      <email>rs3323@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Constance Moussouris</last_name>
      <email>com3001@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering (MSKCC)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harjeet Sembhi</last_name>
      <email>Harjeet.Sembhi@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Dowlin</last_name>
      <phone>832-824-4306</phone>
      <email>Deborah.dowlin@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uday Popat</last_name>
      <email>upopat@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net/</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Heart, Lung, and Blood Institute (NHLBI)</investigator_affiliation>
    <investigator_full_name>Catherine Bollard</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Within 6 months of official study closure at participating sites</ipd_time_frame>
    <ipd_access_criteria>Available to public</ipd_access_criteria>
    <ipd_url>https://biolincc.nhlbi.nih.gov/home/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 24, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT04975698/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

